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Chronic heart failure (HF) imposes a large public health burden in terms of morbidity, 
mortality, and economic cost. HF with reduced left ventricular ejection fraction (LVEF) is 
associated with a hypercoagulable state, formation of left ventricular thrombus, cerebral 
embolism, and death from atherothrombotic events [1]. As such, anticoagulation is 
recommended for HF patients with atrial fibrillation (AF), and considered for those without AF 
but with previous embolic events [2].  
 Warfarin, the current mainstay of anticoagulation in HF, requires frequent monitoring 
and dosing adjustment, and is thus difficult to manage. This difficulty is concerning given that 
poor warfarin control is associated with increased risk of death, myocardial infarction, and stroke 
[3].
 
Further, as most HF patients have reduced heart failure-related quality of life (HFQoL) [4], a 
characteristic that has been associated with medication non-adherence in other patient 
populations [5],
 
treatment with warfarin may present even greater challenges in this population.
 
Although some studies have examined patient factors that predict anticoagulant control [6], the 
effect of HFQoL—a potentially modifiable factor—on anticoagulant control in HF has never 
been investigated.  
In this ancillary analysis of 1,142 participants from the Warfarin and Aspirin in Reduced 
Cardiac Ejection Fraction (WARCEF) trial, we tested whether reduced HFQoL was 
independently associated with poor warfarin control.  
Details of the WARCEF trial have previously been published [1]. Briefly, patients who 
were 18 years of age or older and had HF in normal sinus rhythm, no contraindication to 
warfarin, and a LVEF < 35% or wall-motion index ≤ 1.2 were randomized to receive either 
warfarin or aspirin therapy. Additional eligibility criteria included a modified Rankin score ≤ 4 
and planned treatment with a beta-blocker, angiotensin-converting-enzyme inhibitor, or  
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hydralazine and nitrates. Patients randomized to receive warfarin were managed by local practice 
guidelines with at least monthly international normalized ratio (INR) testing.  
For this study, we included 1,142 participants randomized to warfarin therapy with 
targeted INR between 2.0 and 3.5. The trial was performed in 168 centers from 11 countries 
around the world. All local institutional review committees approved the study protocol, and all 
patients provided informed consent for trial entry. 
 A modified time in therapeutic range (TTR) metric was calculated to estimate warfarin 
control [7]. This method interpolates all available INR values to calculate percentage of days 
when the INR is between 2.0 and 3.5.  
The Minnesota Living with Heart Failure Questionnaire (MLHFQ) was administered at 
randomization [8] as a measure of HFQoL. This 21-item measure requires respondents to 
indicate how much their HF symptoms have interfered with their daily lives during the past 30 
days, using a scale from 0 (not very much) to 5 (very much). Scores on the MLHFQ range from 
0 to 105, with higher scores indicating worse HFQoL. 
 Differences in baseline characteristics by TTR were compared using t tests for continuous 
variables and chi-square tests for discrete characteristics. Beta-logit regression analyses, which 
are used to analyze proportions and yield an odds ratio (OR), were conducted to assess whether 
HFQoL was associated with TTR. We first controlled for age (years) and sex, and then 
additionally controlled for other clinical-demographic factors that have been associated with 
TTR. These included race/ethnicity, education (years), body mass index (kg/m
2
), hypertension, 
diabetes, history of ischemic stroke, recent stroke or transient ischemic attack (within 12 months 
of randomization), peripheral vascular disease, hematocrit, and hemoglobin (g/dL) [9].  
The median TTR was 63% (interquartile range, 39%). Participants whose TTR was  
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below the median were younger, and less likely to be White, non-Hispanic than those with TTR 
was above the median (Table 1). These participants were also more likely to have had 
hypertension and ischemic stroke.  
 In an age- and sex-adjusted regression model (Table 2), baseline HFQoL was 
significantly associated with TTR such that each 10-point increase on the MLHFQ (i.e., 
worsening of HFQoL) corresponded to an 8% decrease in the odds of being in therapeutic range 
(95% confidence interval [CI] = 0.89 – 0.95, p < 0.001). In the fully-adjusted model, HFQoL 
remained significantly associated with TTR (OR = 0.91, 95% CI = 0.87 – 0.96, p < 0.001). 
Additionally, having a recent stroke was associated with a 42% decrease in the odds of being in 
therapeutic range (p = 0.01), and White, non-Hispanic race/ethnicity was associated with a 74% 
increase in the odds (p < 0.001) of being in therapeutic range. 
  In this large cohort of 1,142 patients with HF, we examined for the first time whether 
HFQoL is associated with warfarin control, and found that reduced HFQoL was independently 
associated with reduced odds of being in therapeutic range. Although a previous study found no 
association of quality of life with anticoagulation control, that study was limited by a small 
sample of 52 non-HF patients, a cross-sectional design, and a non-validated measure of quality 
of life [10]. Consistent with previous literature [9], however, we observed associations of White, 
non-Hispanic race/ethnicity with greater odds and recent stroke with reduced odds of being in 
therapeutic range. Given that those with recent stroke have a high recurrent stroke rate, special 
attention needs to be placed on effective anticoagulant control in this population. Apostolakis 
and colleagues recently derived a prediction model for anticoagulant control that included both 
race/ethnicity and stroke (among other medical comorbidities); however, this model did not 
include HFQoL, and thus the incremental value of adding this parameter to their model may be  
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worth examining. Further, although age independently predicted TTR in their model as well as in 
our minimally-adjusted prediction model, its predictive value was attenuated to non-significance 
in our fully-adjusted model. This curious finding may reflect limited statistical power or a 
confounding or mediating effect of other covariates on the age-TTR association—scenarios that 
could be tested in future studies.    
 Of note, we did not assess all potential patient characteristics known to interfere with 
anticoagulant therapy. In addition, we did not include a measure of medication adherence to test 
whether this factor partially explains the association of HFQoL with warfarin control.  
In conclusion, we found that reduced HFQoL is associated with reduced warfarin control 
among HF patients with reduced LVEF in normal sinus rhythm. Future research could consider 
whether intervening to improve HFQoL has beneficial downstream effects on TTR or whether 
newer anticoagulants that do not require frequent dosing adjustments on the basis of a TTR have 
a role in the management of HF patients with poor HFQoL who require systemic 
anticoagulation.  
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Table 1. Baseline parameters for patients above and below the median time in therapeutic range of warfarin 
 
Parameter 
Overall TTR ≥ 63% TTR < 63%  
P N Value
*
 N Value N Value 
Age, years 1,142 60.8 ± 11.6 527 62.2 ± 11.3 540 59.2 ± 11.7 < 0.01 
Female  221 (20.7)  102 (19.4)  119 (22.0) 0.28 
Race/Ethnicity       < 0.01 
     White, non-Hispanic  809 (75.8)  448 (85.0)  361 (66.9)  
     Black, non-Hispanic   149 (14.0)  32 (6.1)  117 (21.7)  
     Hispanic  81 (7.6)  33 (6.3)  48 (8.9)  
     Other  28 (2.6)  14 (2.7)  14 (2.6)  
Education       0.09 
    ≤ Some high school  455 (42.6)  235 (44.6)  220 (40.7)  
       High school  458 (42.9)  209 (40.0)  249 (46.1)  
    ≥ College  154 (14.4)  83 (15.8)  71 (13.2)  
Body mass index, kg/m
2
 1,135 29.0 ± 5.9 524 29.1 ± 5.6 539 29.0 ± 6.3 0.79 
Hypertension  620 (60.1)  286 (56.5)  334 (63.6) 0.02 
Diabetes  347 (32.6)  166 (31.6)  181 (33.6) 0.48 
Ischemic stroke  116 (10.9)  45 (8.6)  71 (13.2) 0.02 
Recent stroke  59 (8.3)  21 (6.6)  37 (9.5) 0.24 
Recent TIA
†
  26 (2.4)  9 (1.7)  17 (3.2) 0.13 
Peripheral vascular disease  130 (12.2)  59 (11.2)  71 (13.2) 0.33 
Hematocrit 1,045 41.7 ± 4.6 481 41.8 ± 4.4 501 41.6 ± 4.8 0.61 
Hemoglobin, g/dL 1,042 14.0 ± 1.6 488 14.0 ± 1.5 489 14.0 ± 1.6 0.72 
MLHFQ
§
 1,132 34.1 ± 23.7 523 29.7 ± 21.6 538 38.9 ± 25.1 <0.01 
NYHA Class III & IV
| |
 1,067 337 (31.6) 527 137 (26.0) 540 200 (37.0) <0.01 
*All values are mean ± standard deviation or N (%). 
†TIA, transient ischemic attack 
§MLHFQ, Minnesota Living with Heart Failure Questionnaire 
| |
NYHA, New York Heart Association 
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*
OR, odds ratio 
†
CI, confidence interval;  
§
MLHFQ, Minnesota Living with Heart Failure Questionnaire 
| |
NYHA, New York Heart Association 
Table 2 Beta-logit regression analysis of predictors of anticoagulant control during warfarin therapy 
 
Parameter 
Model 1 Model 2 
OR
*
 95% CI
†
 P OR 95% CI P 
Age, years 1.01 1.003 - 1.016 0.004 1.002 0.99 - 1.01 0.72 
Female 1.20 1.003 - 1.432 0.047 1.15 0.88 - 1.51 0.41 
MLHFQ
§
, per 10-point increase  0.92 0.89 - 0.95 < 0.001 0.91 0.87 - 0.96 < 0.001 
White, Non-Hispanic    1.74 1.33 - 2.29 < 0.001 
Education, years    0.96 0.83 - 1.13 0.65 
Body mass index, kg/m
2
    1.00 0.98 - 1.02 0.66 
Hypertension    1.18 0.95 - 1.46 0.15 
Diabetes    1.16 0.92 - 1.48 0.21 
Ischemic stroke    1.11 0.80 - 1.53 0.54 
Recent stroke    0.58 0.38 - 0.88 0.01 
Recent transient ischemic attack    0.89 0.45 - 1.77 0.74 
Peripheral vascular disease    0.77 0.55 - 1.06 0.11 
Hematocrit    0.98 0.94 - 1.02 0.23 
Hemoglobin, g/dL    1.00 0.88 - 1.14 0.99 
NYHA Class III & IV
| |
    0.88 0.69 - 1.12 0.30 
